MedTrace Logo

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

NCT05610332 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2022-11-09

No results posted yet for this study

Summary

To evaluate the clinical efficacy of albumin paclitaxel combined with carelizumab and FLOT in the neoadjuvant treatment of locally advanced gastric cancer with different immune types

Conditions

  • Locally Advanced Gastric Cancer

Interventions

DRUG

Camrelizumab

Camrelizumab One course will last 21 days. Given once every 3 weeks at a dose of 200 mg.

DRUG

Albumin Taxol

Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle

DRUG

FLOT scheme

Docetaxel 50mg/m2, ivgtt, d1; Oxaliplatin 85 mg/m2, ivgtt, d1; Calcium folinate 200mg/m2, ivgtt, d1; 5-fluorouracil 2600mg/m2, 24h civ, d1, 4 cycles before and after operation, q2w

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Principal Investigators

  • Chang-Ming Huang, Ph.D. · Fujian Medical University Union Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2024-11-01
Completion
2027-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05610332 on ClinicalTrials.gov